Ritter Pharmaceuticals

Ritter Pharmaceuticals mainly develops novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The company's lead product, RP-G28, has the potential to become the first FDA-approved treatment for lactose intolerance, a condition that affects millions of people worldwide. RP-G28 has been studied in Phase 2 trials and has now entered Phase 3 clinical development. Ritter Pharmaceuticals is further exploring the functionality and discovering the therapeutic potential of altering the gut microbiome for the treatment/prevention of various conditions, including: gastrointestinal diseases, immuno-oncology, metabolic and liver diseases.